CrossrefInfokarte
Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis
World Journal of Oncology · 2025-08 · 16 (4) · 331-341
DOI: 10.14740/wjon2613 ↗Abstract
Kein Abstract verfügbar.
EUVIMED